29.09.2010 • News

Bayer's Yasmin Patent Infringement Claim Dismissed

A U.S. judge on Tuesday dismissed Bayer’s patent lawsuit against Watson Pharmaceuticals and Novartis' Sandoz unit, which are seeking to market generic versions of Bayer's Yasmin birth control pills.

Bayer had alleged that the defendants infringed its patent by seeking U.S. approval to market generic versions of the oral contraceptive. The judge said that Bayer's patent does not claim a use for Yasmin that has been approved by the U.S. Food and Drug Administration.

The company's claim was dismissed "with prejudice," meaning it cannot be brought again.

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.